公开(公告)号：EP0804483B1

公开(公告)日：2000-12-27

申请号：EP95914838.8

申请日：1995-03-22

申请人： LUDWIG INSTITUTE FOR CANCER RESEARCH ,  THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD ,  RIJKSUNIVERSITEIT LEIDEN

发明人： TOWNSEND, Alan Molecular Immunology Group ,  BASTIN, Judy Molecular Immunology Group ,  BOON-FALLEUR, Thierry ,  VAN DER BRUGGEN, Pierrce ,  COULIE, Pierre ,  GAJEWSKI, Thomas ,  MELIEF, Cornelis J.M. ,  VISSEREN, M.W. ,  KAST, W.M.

IPC分类号： C07K14/705 ,  C12N5/06 ,  C07K16/28 ,  A61K38/16 ,  G01N33/576

CPC分类号： C07K14/4748 ,  A61K38/00

摘要： Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.

摘要翻译： 已经鉴定出来自MAGE肿瘤排斥前体的肿瘤排斥抗原。 这些“TRAS”与MHC-I类分子HLA-A2结合，所产生的复合物刺激裂解呈递细胞的溶细胞T细胞克隆的产生。 肽和复合物可以在诊断上，治疗上以及用于产生抗体的免疫原或用作产生溶细胞T细胞克隆的靶标。